Barinthus Biotherapeutics (BRNS) Price & Analysis

Compare

104 Followers

BRNS Stock Chart & Stats

$1.37

>-$0.01(-0.43%)

At close: Jan 08 4:00 PM EST

$1.37

>-$0.01(-0.43%)

Day’s Range― - ―

52-Week Range$0.64 - $2.92

Previous CloseN/A

Volume10.26K

Average Volume (3M)124.73K

Market Cap

$30.17M

Enterprise Value-$13.18M

Total Cash (Recent Filing)$74.27M

Total Debt (Recent Filing)$11.57M

Price to Earnings (P/E)―

Beta2.01

Next Earnings

Mar 20, 2026

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.36

Shares Outstanding40,830,353

10 Day Avg. Volume97,530

30 Day Avg. Volume124,726

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)0.37

Price to Sales (P/S)3.18

P/FCF Ratio-1.60

Enterprise Value/Market Cap-0.44

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.19

Forecast

1Y Price Target

$4.00

Price Target Upside191.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1.55

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessBarinthus Biotherapeutics reported positive data from the single ascending dose (SAD) portion of the first-in-human Phase 1 AVALON trial of VTP-1000 in adults with celiac disease.

Merger And AcquisitionThe combination with Clywedog Therapeutics is expected to close in the first half of 2026, potentially strengthening the company's portfolio with assets for the treatment of metabolic and autoimmune diseases.

Stock Rating And Price TargetThe analyst reiterates a Buy rating while adjusting the 12-month price target to $4 from $3 per share.

Bears Say

Barinthus Biotherapeutics News

Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000

Barinthus Biotherapeutics (BRNS) announced an update on its first-in-human Phase 1 trial of VTP-1000 in adults with celiac...

11d ago

BRNS

Promising Clinical Trial Results and Strategic Merger Drive Buy Rating for Barinthus Biotherapeutics

Barinthus Biotherapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from...

10d ago

BRNS

Barinthus Biotherapeutics Updates on AVALON Trial Progress

Barinthus Biotherapeutics ( ($BRNS) ) has provided an announcement. On December 10, 2025, Barinthus Biotherapeutics announced an update...

11d ago

BRNS

Buy Rating for Barinthus Biotherapeutics: Promising Clinical Developments and Strategic Merger with Clywedog Therapeutics

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Barinthus Biotherapeutics today and set a price target...

1M ago

BRNS

Barinthus Biotherapeutics price target raised to $4 from $3 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Barinthus Biotherapeutics (BRNS) to $4 from $3 and keeps a...

1M ago

BRNS

Barinthus Biotherapeutics Reports Q3 2025 Earnings

Barinthus Biotherapeutics Plc ( ($BRNS) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

BRNS

Barinthus Biotherapeutics reports Q3 EPS (36c) vs (21c) last year

“The proposed combination of Barinthus Bio and Clywedog represents an important step toward building a stronger, more resilient...

1M ago

BRNS

Barinthus Biotherapeutics Advances Celiac Disease Treatment with VTP-1000 Trial

Barinthus Biotherapeutics Plc (($BRNS)) announced an update on their ongoing clinical study. Barinthus Biotherapeutics Plc is conducting a...

2M ago

BRNS

Barinthus Biotherapeutics Announces Merger with Clywedog Therapeutics

Barinthus Biotherapeutics ( ($BRNS) ) has provided an announcement. On September 29, 2025, Barinthus Biotherapeutics and Clywedog Therapeutics...

3M ago

BRNS

Barinthus Bio, Clywedog enter definitive merger agreement

Barinthus Biotherapeutics (BRNS) and Clywedog Therapeutics entered into a definitive merger agreement to combine in an all-stock transaction....

3M ago

BRNS

Barinthus Biotherapeutics: Promising Clinical Developments and Strong Financial Position Justify Buy Rating

H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on BRNS stock, giving a Buy rating yesterday....

5M ago

BRNS

Barinthus Biotherapeutics Reports Q2 2025 Financial Results

Barinthus Biotherapeutics Plc ( ($BRNS) ) has released its Q2 earnings. Here is a breakdown of the information...

5M ago

BRNS

Barinthus Biotherapeutics reports Q2 EPS (52c) vs. (49c) last year

“In the second quarter, we remained laser-focused on advancing VTP-1000, our highly differentiated immunotherapy designed to prevent or...

5M ago

BRNS

Barinthus Biotherapeutics sees cash runway into 2027

As of June 30, 2025, cash, cash equivalents and restricted cash was $87.8 million, compared to $100.6 million...

5M ago

BRNS

BRNS FAQ

What was Barinthus Biotherapeutics Plc’s price range in the past 12 months?

Barinthus Biotherapeutics Plc lowest stock price was $0.64 and its highest was $2.92 in the past 12 months.

What is Barinthus Biotherapeutics Plc’s market cap?

Barinthus Biotherapeutics Plc’s market cap is $30.17M.

When is Barinthus Biotherapeutics Plc’s upcoming earnings report date?

Barinthus Biotherapeutics Plc’s upcoming earnings report date is Mar 20, 2026 which is in 89 days.

How were Barinthus Biotherapeutics Plc’s earnings last quarter?

Barinthus Biotherapeutics Plc released its earnings results on Nov 07, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.395 by $0.035.

Is Barinthus Biotherapeutics Plc overvalued?

According to Wall Street analysts Barinthus Biotherapeutics Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Barinthus Biotherapeutics Plc pay dividends?

Barinthus Biotherapeutics Plc does not currently pay dividends.

What is Barinthus Biotherapeutics Plc’s EPS estimate?

Barinthus Biotherapeutics Plc’s EPS estimate is -0.35.

How many shares outstanding does Barinthus Biotherapeutics Plc have?

Barinthus Biotherapeutics Plc has 40,830,353 shares outstanding.

What happened to Barinthus Biotherapeutics Plc’s price movement after its last earnings report?

Barinthus Biotherapeutics Plc reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.395. Following the earnings report the stock price went down -10.084%.

Which hedge fund is a major shareholder of Barinthus Biotherapeutics Plc?

Currently, no hedge funds are holding shares in BRNS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Barinthus Biotherapeutics Plc

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Barinthus Biotherapeutics (BRNS) Earnings & Revenues

Historic Earnings Reports

BRNS Stock 12 Month Forecast

Average Price Target

$4.00

▲(191.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.76,1.0092307692307694,1.2584615384615385,1.5076923076923077,1.756923076923077,2.006153846153846,2.2553846153846155,2.504615384615385,2.753846153846154,3.0030769230769234,3.252307692307692,3.5015384615384617,3.7507692307692313,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.76,1.0092307692307694,1.2584615384615385,1.5076923076923077,1.756923076923077,2.006153846153846,2.2553846153846155,2.504615384615385,2.753846153846154,3.0030769230769234,3.252307692307692,3.5015384615384617,3.7507692307692313,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.76,1.0092307692307694,1.2584615384615385,1.5076923076923077,1.756923076923077,2.006153846153846,2.2553846153846155,2.504615384615385,2.753846153846154,3.0030769230769234,3.252307692307692,3.5015384615384617,3.7507692307692313,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.98,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >